A novel vitamin C preparation enhances neurite formation and fibroblast adhesion and reduces xenobiotic-induced T-cell hyperactivation.
BACKGROUND
Vitamin C (ascorbic acid, ascorbate) has been shown to enhance neurite outgrowth, promote fibroblast adhesion during wound healing, and reduce xenobiotic-induced leukocyte hyperactivity and inflammatory damage. In this study, a comparison was made between Ester-C and PureWay-C on these various cellular activities.


METHODS
PC12 cells were stimulated to form neurites with nerve growth factor, NIH 3T3 fibroblasts were seeded on fibronectin and H9 T-cells were stimulated to aggregate with the pyrethroid pesticide bifenthrin. The rate of neurite formation, fibroblast adhesion and T-cell homotypic aggregation was then measured in the absence and presence of various formulations of vitamin C including Ester-C and PureWay-CTM.


RESULTS
With PureWay-C treatment, 12% of PC12 cells extended neurites within one hour of treatment and 45% of the cells extended neurites by hour nine. With Ester-C, 0% and 15% extended neurites at one and nine hours, respectively. NIH-3T3 fibroblast adhesion to fibronectin was enhanced by 4.7-fold with a 30 minute PureWay-CTM treatment while Ester-C increased fibroblast adhesion by only 1.5 fold. Further, PureWay-CTM reduced pesticide-mediated T-cell homotypic aggregation by 83% within 30 minutes of treatment while the reduction seen with Ester-C was only 33%.


CONCLUSIONS
These data confirm the previous observations that vitamin C supplementation can promote neurite outgrowth, increase fibroblast adhesion and reduce xenobiotic induce immunocytes aggregation. More importantly, these data show that PureWay-C has a faster and greater beneficial effect on these parameters when compared to other vitamin C formulations.
Weeks
Benjamin S
BS
Department of Biology and Environmental Sciences Program, Adelphi University, Garden City, NY, USA.
Perez
Pedro P
PP
D000818:Animals; D001205:Ascorbic Acid / Q000494:pharmacology*; D002448:Cell Adhesion / Q000187:drug effects; D002449:Cell Aggregation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005347:Fibroblasts / Q000166:cytology* / Q000187:drug effects*; D005353:Fibronectins / Q000378:metabolism; D006801:Humans; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology*; D051379:Mice; D041681:NIH 3T3 Cells; D009414:Nerve Growth Factors / Q000494:pharmacology; D016501:Neurites / Q000187:drug effects*; D016716:PC12 Cells; D010835:Phytohemagglutinins / Q000494:pharmacology; D011722:Pyrethrins / Q000494:pharmacology; D051381:Rats; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*; D015262:Xenobiotics / Q000494:pharmacology*
D005353:Fibronectins; D009414:Nerve Growth Factors; D010835:Phytohemagglutinins; D011722:Pyrethrins; D015262:Xenobiotics; C099952:bifenthrin; D001205:Ascorbic Acid